Alteration Of Name On 1 October 2008

Matching for 'Alteration of Name' during October 2008.



Contents

Alerts	3
1 event	3
Terms and Conditions	6
General	6
Disclaimer of warranty and limitation of liability	6
Copyright	6
Arbitration	6

Alerts

1 event

94 results matching for 'Alteration of Name' during October 2008.

Number	Title	Date
2002343279	Sensitivity controls for blood serology prepared from modified cells	01 Oct 2008
2003204582	Reel	01 Oct 2008
2003217930	The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents	01 Oct 2008
2003219779	Novel Vip3 toxins and methods of use	01 Oct 2008
2003226065	Recombinant anti-interleukin-9 antibodies	01 Oct 2008
2003243228	EphA2 monoclonal antibodies and methods of use thereof	01 Oct 2008
2003248295	Apparatus for Measuring Water Concentration in Multi-Component Solutions	01 Oct 2008
2003250866	Merocyanine derivatives for cosmetic use	01 Oct 2008
2003256823	Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies	01 Oct 2008
2003273299	Methods of preventing or treating cell malignancies by administering CD2 antagonists	01 Oct 2008
2003276402	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations	01 Oct 2008
2003276832	EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF	01 Oct 2008
2003285777	3-substituted-4-pyrimidone derivatives	01 Oct 2008
2003286259	Improved inhalation method and apparatus	01 Oct 2008
2003286935	Gas cleaning process and equipment therefor	01 Oct 2008
2004207003	Anti-integrin alphanubeta3 antibody formulations and uses thereof	01 Oct 2008
2004223987	2, 3, 6-trisubstituted-4-pyrimidone derivatives	01 Oct 2008
2004229501	Recombinant IL-9 antibodies and uses thereof	01 Oct 2008
2004229527	Methods of preventing or treating respiratory conditions	01 Oct 2008
2004229543	EphA2 and non-neoplastic hyperproliferative cell disorders	01 Oct 2008
2004230539	EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution	01 Oct 2008
2004247217	Modular jack assembly	01 Oct 2008
2004257748	Method of diagnosis and treatment for asthma based on haplotype association	01 Oct 2008
2004261603	EphA2 T-cell epitope agonists and uses therefor	01 Oct 2008
2004262115	Analysing biological entities	01 Oct 2008
2004280333	Humanization of antibodies	01 Oct 2008
2004285993	Leach extraction method	01 Oct 2008
2004286198	Humanization of antibodies	01 Oct 2008
2004308328	Multi plasmid system for the production of influenza virus	01 Oct 2008
2005200519	Method and manufacture of corrosion resistant and decorative coatings and laminated systems for metal substrates	01 Oct 2008
2005202542	Hanger for a cable	01 Oct 2008
2005248375	Influenza hemagglutinin and neuraminidase varians	01 Oct 2008
2005248377	Influenza hemagglutinin and neuraminidase variants	01 Oct 2008
2005272396	Antibody and utilization of the same	01 Oct 2008
2005277641	Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity	01 Oct 2008
2005279707	A zirconia ceramic	01 Oct 2008

www.ipmonitor.com.au 3 of 6

Number	Title	Date
2005280885	2-morpholino-4-pyrimidone compound	01 Oct 2008
2005286770	Antibodies against and methods for producing vaccines for respiratory syncytial virus	01 Oct 2008
2005288045	6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors	01 Oct 2008
2005294528	Refrigerator-temperature stable influenza vaccine compositions	01 Oct 2008
2005295158	High cell density process for growth of Listeria	01 Oct 2008
2005299353	Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections	01 Oct 2008
2005299354	Modulators of EphA2 and ephrina1 for the treatment of fibrosis-related disease	01 Oct 2008
2005299355	Modulation of antibody specificity by tailoring the affinity to cognate antigens	01 Oct 2008
2005302274	Ultra high throughput capture lift screening methods	01 Oct 2008
2005302453	Methods of preventing and treating RSV infections and related conditions	01 Oct 2008
2005314138	Methods of producing influenza vaccine compositions	01 Oct 2008
2005322353	Non-tumorigenic MDCK cell line for propagating viruses	01 Oct 2008
2005333602	High affinity antibodies against HMGB1 and methods of use thereof	01 Oct 2008
2006203015	Ultra high affinity neutralizing antibodies	01 Oct 2008
2006203134	Methods of administering/dosing antiRSV antibodies for prophylaxis and treatment	01 Oct 2008
2006211586	Integrated reporting of data	01 Oct 2008
2006223002	Macromolecules comprising a thioether cross-link	01 Oct 2008
2006223138	Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus	01 Oct 2008
2006226861	Treatment of protein degradation disorders	01 Oct 2008
2006227377	Framework-shuffling of antibodies	01 Oct 2008
2006230713	Retractable image projecting system	01 Oct 2008
2006234847	Antibodies against mammalian metapneumovirus	01 Oct 2008
2006239851	Modulation of antibody effector function by hinge domain engineering	01 Oct 2008
2006262380	Methods and compositions for expressing a heterologous protease	01 Oct 2008
2006262381	Methods and compositions for expressing negative-sense viral RNA in canine cells	01 Oct 2008
2006265936	An integrated approach for generating multidomain protein therapeutics	01 Oct 2008
2006269577	Soil conditioning device	01 Oct 2008
2006287416	Toxin conjugated Eph receptor antibodies	01 Oct 2008
2006297304	Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells	01 Oct 2008
2006304387	Cell display of antibody libraries	01 Oct 2008
2006304898	Multi-plasmid system for the production of influenza virus	01 Oct 2008
<u>2006327175</u>	Epha2 bite molecules and uses thereof	01 Oct 2008
2006330072	Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors	01 Oct 2008
2006330807	Antagonists of HMBG1 and/or rage and methods of use thereof	01 Oct 2008
2006331775	Affinity optimized EphA2 agonistic antibodies and methods of use thereof	01 Oct 2008
2006339993	Prosthetic device and system and method for implanting prosthetic device	01 Oct 2008
2006340728	Enhanced method for signal shaping in multi-channel audio reconstruction	01 Oct 2008
2007201825	Recombinant parainfluenza virus expression systems and vaccines	01 Oct 2008
2007206011	Match-based employment system and method	01 Oct 2008
2007206736	Cooking apparatus	01 Oct 2008
2007209859	Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients	01 Oct 2008
2007212147	Protein formulations	01 Oct 2008
<u>2007213355</u>	Formulations of clopidogrel bisulphate	01 Oct 2008

www.ipmonitor.com.au 4 of 6

Number	Title	Date
2007217879	Mid-IR laser instrument for analyzing a gaseous sample and method for using the same	01 Oct 2008
2007221225	Collagenase for treating cellulite	01 Oct 2008
2007225183	Electrically pumped broadly tunable mid-infrared lasers based on quantum confined transition metal doped semiconductors	01 Oct 2008
2007233605	Method and equipment for treating process gas	01 Oct 2008
2007240198	Push-up exercise unit and device	01 Oct 2008
2007282140	Laser energy calibration based on optical measurement	01 Oct 2008
2008200376	A substantially visibly transparent topical physical sunscreen formulation	01 Oct 2008
2008200401	Recombinant RSV virus expression systems and vaccines	01 Oct 2008
2008200748	A portable image projection device	01 Oct 2008
2008201113	Recombinant RSV virus expression systems and vaccines	01 Oct 2008
2008201162	Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphavbeta3 antagonists in combination with other prophylactic or therapeutic agents	01 Oct 2008
2008201412	Combination therapy of respiratory diseases using antibodies and antiinflammatory agents	01 Oct 2008
2008201419	Molecules with extended half-lives, compositions and uses thereof	01 Oct 2008
2008202076	Methods of administering/dosing antiRSV antibodies for prophylaxis and treatment	01 Oct 2008
2008202925	Stabilized liquid anti-RSV antibody formulations	01 Oct 2008

www.ipmonitor.com.au 5 of 6

Terms and Conditions

General

The information provided in this report is not in the nature of legal or other professional advice.

The information provided in this report is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals regarding any information in this report.

Patents, patent applications, trademarks and trademark applications shown as lapsed or ceased may be restored at a later date.

Disclaimer of warranty and limitation of liability

Neither IPMonitor, its affiliates nor any of their respective employees, agents, third party content providers or licensors warrant that the information contained in this report is error free; nor do they make any warranty as to the accuracy, reliability or content of any information in this report.

This report is provided on an "as is" basis; to the maximum extent permitted by law, IPMonitor disclaims all representations and warranties, express or implied, with respect to any information conatined in this report. In addition, IPMonitor does not represent or warrant that the information contained in this report is accurate, complete or current.

This disclaimer of liability applies to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action.

Copyright

The content of this report may be protected by copyright laws and treaties around the world and all rights relating to the same are reserved. Any paper or digital copies of this report are not to be modified or any illustrations or any graphics used separately from any accompanying text.

Arbitration

Any dispute or difference whatsoever arising out of or in connection with this report shall be submitted to arbitration in accordance with, and subject to, The Institute of Arbitrators & Mediators Australia Rules for the Conduct of Commercial Arbitrations.

IPMonitor reserves the right to update the Terms and Conditions at any time without notice. Please see the full Terms and Conditions at www.IPMonitor.com.au/trademarks/info/terms

www.ipmonitor.com.au 6 of 6